The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study
Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship...
Saved in:
| Published in | PLoS medicine Vol. 19; no. 1; p. e1003859 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
27.01.2022
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1549-1676 1549-1277 1549-1676 |
| DOI | 10.1371/journal.pmed.1003859 |
Cover
| Abstract | Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa.
Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings.
We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. |
|---|---|
| AbstractList | BackgroundNumerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa.Methods and findingsData for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings.ConclusionsWe observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. Background Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa. Methods and findings Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (OR.sub.weighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (OR.sub.IVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR OR.sub.IVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR OR.sub.IVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings. Conclusions We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. Anna Ioannidou and colleagues investigate the relationship between genetically predicted blood lipid concentrations and prostate cancer. Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa. Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (OR.sub.weighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (OR.sub.IVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR OR.sub.IVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR OR.sub.IVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings. We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. Background Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa. Methods and findings Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings. Conclusions We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. Background Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa. Methods and findings Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings. Conclusions We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa.BACKGROUNDNumerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa.Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings.METHODS AND FINDINGSData for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings.We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies.CONCLUSIONSWe observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The ongoing research has mainly involved observational studies, which are often prone to confounding. This study aimed to identify the relationship between genetically predicted blood lipid concentrations and PCa. Data for low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides (TG), apolipoprotein A (apoA) and B (apoB), lipoprotein A (Lp(a)), and PCa were acquired from genome-wide association studies in UK Biobank and the PRACTICAL consortium, respectively. We used a two-sample summary-level Mendelian randomisation (MR) approach with both univariable and multivariable (MVMR) models and utilised a variety of robust methods and sensitivity analyses to assess the possibility of MR assumptions violation. No association was observed between genetically predicted concentrations of HDL, TG, apoA and apoB, and PCa risk. Genetically predicted LDL concentration was positively associated with total PCa in the univariable analysis, but adjustment for HDL, TG, and Lp(a) led to a null association. Genetically predicted concentration of Lp(a) was associated with higher total PCa risk in the univariable (ORweighted median per standard deviation (SD) = 1.091; 95% CI 1.028 to 1.157; P = 0.004) and MVMR analyses after adjustment for the other lipid traits (ORIVW per SD = 1.068; 95% CI 1.005 to 1.134; P = 0.034). Genetically predicted Lp(a) was also associated with advanced (MVMR ORIVW per SD = 1.078; 95% CI 0.999 to 1.163; P = 0.055) and early age onset PCa (MVMR ORIVW per SD = 1.150; 95% CI 1.015,1.303; P = 0.028). Although multiple estimation methods were utilised to minimise the effect of pleiotropy, the presence of any unmeasured pleiotropy cannot be excluded and may limit our findings. We observed that genetically predicted Lp(a) concentrations were associated with an increased PCa risk. Future studies are required to understand the underlying biological pathways of this finding, as it may inform PCa prevention through Lp(a)-lowering strategies. |
| Audience | Academic |
| Author | Tsilidis, Konstantinos K. Platz, Elizabeth A. Travis, Ruth C. Perez-Cornago, Aurora Ioannidou, Anna Watts, Eleanor L. Mills, Ian G. Zuber, Verena Key, Timothy J. |
| AuthorAffiliation | 1 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom 2 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom 3 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America 8 Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway 5 Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America 4 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States of America 6 Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom 7 Patrick G Johnston Centre for Cancer Research (PGJCCR), Queen’s University Belfast, Belfast, United Kingdom 9 Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Gr |
| AuthorAffiliation_xml | – name: 4 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States of America – name: 7 Patrick G Johnston Centre for Cancer Research (PGJCCR), Queen’s University Belfast, Belfast, United Kingdom – name: 3 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America – name: 6 Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom – name: 2 Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom – name: 5 Department of Urology and the James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America – name: 9 Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece – name: Peter MacCallum Cancer Centre, AUSTRALIA – name: 1 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom – name: 8 Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway |
| Author_xml | – sequence: 1 givenname: Anna orcidid: 0000-0003-2795-8174 surname: Ioannidou fullname: Ioannidou, Anna – sequence: 2 givenname: Eleanor L. orcidid: 0000-0001-9229-2589 surname: Watts fullname: Watts, Eleanor L. – sequence: 3 givenname: Aurora orcidid: 0000-0002-5652-356X surname: Perez-Cornago fullname: Perez-Cornago, Aurora – sequence: 4 givenname: Elizabeth A. orcidid: 0000-0003-3676-8954 surname: Platz fullname: Platz, Elizabeth A. – sequence: 5 givenname: Ian G. surname: Mills fullname: Mills, Ian G. – sequence: 6 givenname: Timothy J. orcidid: 0000-0003-2294-307X surname: Key fullname: Key, Timothy J. – sequence: 7 givenname: Ruth C. orcidid: 0000-0002-9571-0763 surname: Travis fullname: Travis, Ruth C. – sequence: 8 givenname: Konstantinos K. orcidid: 0000-0002-8452-8472 surname: Tsilidis fullname: Tsilidis, Konstantinos K. – sequence: 9 givenname: Verena orcidid: 0000-0001-9827-1877 surname: Zuber fullname: Zuber, Verena |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35085228$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVk11rFDEUhgepWFv9B6IDgujFrslMJpnphVCKH4VqQau3IZOc7KRmkzXJtPbOn252u5VuWUSZiwznPOc9Sd6cvWLHeQdF8QSjKa4Zfn3ux-CEnS7moKYYobptunvFQ9yQboIpozu3_neLvRjPEao61KEHxW7doLapqvZh8etsgDKAFcl4FwezKHtIlwCutGbhF8EnMK48LIVTpU8DhGXcqFhemjSUOR-TSFBK4WTOBRO_H2R6PtpkLkQwordQfgSnwBrhypBl_NzEVbcyplFdPSrua2EjPF6v-8XXd2_Pjj5MTk7fHx8dnkwkoyRNtMKYYtr3Pa5owyrCWlxh1OKeISYVJoR1SiPQoKtadTVBbceaFndC0opoUe8Xz651F9ZHvr68yCtGK9zWjLWZOL4mlBfnfBHMXIQr7oXhq4APMy5CMtICbzqimKQaSy2J0Eow2mMkFaKCqlY3WevNutvYZ38kuBSE3RDdzDgz8Jm_4C3rSPYoC7xcCwT_Y4SYeL42CdYKB37M-6ZV3bbZc5LR53fQ7adbUzORD2Cc9rmvXIryQ9phgklHcKYmW6gZOMibzO9Pmxze4Kdb-PwpmBu5teDVRkFmEvxMMzHGyI-_fP4P9tO_s6ffNtkXt9gBhE1D9HZcjcAm-PS2i3_suxmfDBxcAzIPQgyguTRp9bjzNRjLMeLLWb0xhC9nla9nNReTO8U3-n8t-w0eWELe |
| CitedBy_id | crossref_primary_10_1016_j_atherosclerosis_2022_04_015 crossref_primary_10_3389_fnut_2024_1356207 crossref_primary_10_1371_journal_pmed_1004362 crossref_primary_10_1016_j_lfs_2024_123035 crossref_primary_10_3389_fonc_2023_1108633 crossref_primary_10_1007_s44178_024_00105_9 crossref_primary_10_3390_nu14071367 crossref_primary_10_1007_s12672_024_01493_0 crossref_primary_10_3390_genes15010132 crossref_primary_10_1097_HCO_0000000000001104 crossref_primary_10_1007_s40618_023_02153_w crossref_primary_10_1136_heartjnl_2022_321396 crossref_primary_10_1016_j_atherosclerosis_2023_02_001 crossref_primary_10_12677_acm_2025_151197 crossref_primary_10_3389_fonc_2024_1442911 crossref_primary_10_1007_s00432_023_04791_2 crossref_primary_10_1371_journal_pmed_1003988 crossref_primary_10_1002_hsr2_70528 crossref_primary_10_3892_mco_2025_2829 crossref_primary_10_7717_peerj_17827 crossref_primary_10_1002_cam4_5204 crossref_primary_10_1136_openhrt_2023_002382 crossref_primary_10_1002_cam4_5463 crossref_primary_10_1007_s10552_024_01853_9 crossref_primary_10_1002_cam4_70587 crossref_primary_10_1038_s41598_024_80190_y crossref_primary_10_1007_s00262_024_03633_5 |
| Cites_doi | 10.1002/cam4.695 10.1194/jlr.R083626 10.1093/jnci/djaa154 10.1007/s11789-017-0084-1 10.1038/s41467-019-13870-3 10.1002/gepi.21758 10.4103/1008-682X.156854 10.1158/1055-9965.EPI-18-0079 10.1158/1055-9965.EPI-19-0145 10.1016/j.ebiom.2020.102721 10.1158/1078-0432.CCR-18-1060 10.1016/j.ajhg.2016.05.013 10.1002/ijc.23715 10.1038/s41416-020-01081-3 10.1158/1055-9965.EPI-09-0472 10.1194/jlr.R067314 10.1186/s12916-017-0976-4 10.1038/pcan.2010.3 10.1093/bioinformatics/btz469 10.1007/s40471-017-0128-6 10.1371/journal.pone.0039445 10.1093/bioinformatics/btw373 10.1001/jamacardio.2018.1470 10.1038/s41588-018-0099-7 10.1002/ijc.30013 10.14740/wjon1191 10.1038/s41588-018-0142-8 10.1158/1055-9965.EPI-17-1177 10.1016/S0140-6736(16)31009-1 10.1101/cshperspect.a030387 10.1038/s41467-019-14156-4 10.1194/jlr.R053066 10.1093/ije/dyu005 10.1136/bmj.e7325 10.1158/1055-9965.EPI-09-0322 10.1158/1055-9965.EPI-14-1329 10.1001/jama.2021.18236 10.1007/s40471-018-0152-1 10.1038/s41569-018-0153-2 10.1371/journal.pone.0046691 10.1007/s10557-016-6648-3 10.1194/jlr.R051904 10.1111/j.1365-2796.2012.02592.x 10.1002/sim.7492 10.1101/cshperspect.a030361 10.1258/acb.2011.011111 10.3945/ajcn.115.118216 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2022 Public Library of Science This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: COPYRIGHT 2022 Public Library of Science – notice: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS |
| CorporateAuthor_xml | – name: The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS – name: PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISN ISR 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA CZK |
| DOI | 10.1371/journal.pmed.1003859 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Canada Gale In Context: Science ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals PLoS Medicine |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Lipoprotein A and prostate cancer risk |
| EISSN | 1549-1676 |
| ExternalDocumentID | 2762183778 oai_doaj_org_article_594d7c6f1cfc4afda76b10cd06a6d8f5 PMC8794090 A691414941 35085228 10_1371_journal_pmed_1003859 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom United Kingdom--UK |
| GeographicLocations_xml | – name: United Kingdom – name: United Kingdom--UK |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: C18281/A29019 – fundername: Medical Research Council grantid: MR/W029790/1 – fundername: Cancer Research UK grantid: 29019 – fundername: Cancer Research UK grantid: 29017 – fundername: NCI NIH HHS grantid: UG1 CA189974 – fundername: NCI NIH HHS grantid: UM1 CA182883 – fundername: Cancer Research UK grantid: 28516 – fundername: Cancer Research UK grantid: C60192/A28516 – fundername: ; grantid: C60192/A28516 – fundername: ; grantid: Early Career Research Fellowship – fundername: ; grantid: 2019/1953 – fundername: ; grantid: C18281/A29019 |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAUCC AAWOE AAWTL AAYXX ABDBF ABUWG ACGFO ACIHN ACPRK ACUHS ADBBV AEAQA AENEX AFKRA AFPKN AFRAH AFXKF AHMBA AKRSQ ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS B0M BAWUL BCNDV BENPR BPHCQ BVXVI BWKFM CCPQU CITATION CS3 DIK DU5 E3Z EAP EAS EBD EBS EJD EMK EMOBN ESX F5P FPL FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR IHW INH INR IOF IOV IPO ISN ISR ITC KQ8 M1P M48 MK0 O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PV9 RNS RPM RZL SV3 TR2 TUS UKHRP WOW XSB YZZ ~8M ADRAZ ADXHL CGR CUY CVF ECM EIF H13 IPNFZ NPM PJZUB PPXIY RIG WOQ PMFND 3V. 7TK 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM AAPBV ABPTK ACDSR BCGST CZK ICW M~E UMP |
| ID | FETCH-LOGICAL-c764t-fd11616bbb126572478121081b707cd14479df0efef23d93408975819ac624fa3 |
| IEDL.DBID | M48 |
| ISSN | 1549-1676 1549-1277 |
| IngestDate | Sun Feb 05 03:15:35 EST 2023 Wed Aug 27 01:31:03 EDT 2025 Thu Aug 21 14:37:35 EDT 2025 Thu Sep 04 18:21:46 EDT 2025 Fri Jul 25 07:13:50 EDT 2025 Tue Jun 17 21:03:02 EDT 2025 Thu Jun 12 23:45:58 EDT 2025 Tue Jun 10 20:25:49 EDT 2025 Fri Jun 27 04:24:46 EDT 2025 Fri Jun 27 03:54:03 EDT 2025 Fri Jun 27 03:38:58 EDT 2025 Thu May 22 21:22:02 EDT 2025 Mon Jul 21 05:45:43 EDT 2025 Thu Apr 24 23:04:12 EDT 2025 Tue Jul 01 04:28:26 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication. Creative Commons CC0 public domain |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c764t-fd11616bbb126572478121081b707cd14479df0efef23d93408975819ac624fa3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 I have read the journal’s policy and the authors of this manuscript have the following competing interests: VZ is a paid statistical consultant on PLOS Medicine’s statistical board. Members from the PRACTICAL Consortium, CRUK, BPC3, CAPS, and PEGASUS are provided in the Acknowledgments section. |
| ORCID | 0000-0003-3676-8954 0000-0003-2294-307X 0000-0002-8452-8472 0000-0003-2795-8174 0000-0001-9229-2589 0000-0002-5652-356X 0000-0002-9571-0763 0000-0001-9827-1877 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pmed.1003859 |
| PMID | 35085228 |
| PQID | 2762183778 |
| PQPubID | 1436338 |
| ParticipantIDs | plos_journals_2762183778 doaj_primary_oai_doaj_org_article_594d7c6f1cfc4afda76b10cd06a6d8f5 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8794090 proquest_miscellaneous_2623883854 proquest_journals_2762183778 gale_infotracmisc_A691414941 gale_infotracgeneralonefile_A691414941 gale_infotracacademiconefile_A691414941 gale_incontextgauss_ISR_A691414941 gale_incontextgauss_ISN_A691414941 gale_incontextgauss_IOV_A691414941 gale_healthsolutions_A691414941 pubmed_primary_35085228 crossref_citationtrail_10_1371_journal_pmed_1003859 crossref_primary_10_1371_journal_pmed_1003859 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20220127 |
| PublicationDateYYYYMMDD | 2022-01-27 |
| PublicationDate_xml | – month: 1 year: 2022 text: 20220127 day: 27 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PLoS medicine |
| PublicationTitleAlternate | PLoS Med |
| PublicationYear | 2022 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | JMB Rees (pmed.1003859.ref023) 2019; 14 H Shi (pmed.1003859.ref019) 2016; 99 JMB Rees (pmed.1003859.ref026) 2017; 36 P Rawla (pmed.1003859.ref001) 2019; 10 A Wang (pmed.1003859.ref032) 2019; 28 pmed.1003859.ref017 LM Hurwitz (pmed.1003859.ref007) 2021; 113 TR Rebbeck (pmed.1003859.ref049) 2018; 8 SJ Weinstein (pmed.1003859.ref035) 2009; 18 NR Perdana (pmed.1003859.ref005) 2016; 48 S Burgess (pmed.1003859.ref024) 2013; 37 CD Adams (pmed.1003859.ref015) 2019; 28 FR Schumacher (pmed.1003859.ref020) 2018; 50 JC Van Capelleveen (pmed.1003859.ref041) 2016; 57 CH Pernar (pmed.1003859.ref004) 2018; 8 J Zheng (pmed.1003859.ref013) 2017; 4 EA Platz (pmed.1003859.ref056) 2008; 123 N Sinnott-Armstrong (pmed.1003859.ref018) 2021 W Tang (pmed.1003859.ref051) 2018; 24 V Zuber (pmed.1003859.ref058) 2020; 11 NJ Viney (pmed.1003859.ref060) 2016; 388 MH Dominiczak (pmed.1003859.ref016) 2011; 48 M Loda (pmed.1003859.ref003) 2016 S Burgess (pmed.1003859.ref027) 2018; 3 pmed.1003859.ref002 S Burgess (pmed.1003859.ref022) VW Skrivankova (pmed.1003859.ref039) 2021; 326 TJ Murtola (pmed.1003859.ref046) 2012; 7 CJ Bull (pmed.1003859.ref014) 2016; 5 RC Maranhão (pmed.1003859.ref031) 2014; 103 PC Haycock (pmed.1003859.ref054) 2016; 103 D Bansal (pmed.1003859.ref009) 2012; 7 MA Moyad (pmed.1003859.ref006) 2015; 17 M Verbanck (pmed.1003859.ref029) 2018; 50 NM Davies (pmed.1003859.ref012) 2018 F Kronenberg (pmed.1003859.ref028) 2013; 273 A Perez-Cornago (pmed.1003859.ref045) 2020; 123 B Enkhmaa (pmed.1003859.ref048) 2016; 57 MA Kamat (pmed.1003859.ref037) 2019; 35 MB Boffa (pmed.1003859.ref047) 2019; 16 K Schmidt (pmed.1003859.ref040) 2016; 57 L Yu Peng (pmed.1003859.ref008) 2015; 24 J Yarmolinsky (pmed.1003859.ref011) 2018; 27 S Borgquist (pmed.1003859.ref043) 2016; 138 S Burgess (pmed.1003859.ref038) 2014; 43 P Tan (pmed.1003859.ref010) 2016; 6 LL Bañez (pmed.1003859.ref033) 2010; 13 JR Staley (pmed.1003859.ref036) 2016; 32 EA Platz (pmed.1003859.ref055) 2009; 18 JC Hopewell (pmed.1003859.ref034) 2018; 59 E Orsó (pmed.1003859.ref052) 2017; 12 S Burgess (pmed.1003859.ref057) 2012; 345 F Kronenberg (pmed.1003859.ref059) 2016; 30 VA Katzke (pmed.1003859.ref042) 2017; 15 J Bowden (pmed.1003859.ref025) 2016; 45 S Fatumo (pmed.1003859.ref053) 2020; 54 J Labrecque (pmed.1003859.ref021) 2018; 5 S Burgess (pmed.1003859.ref030) 2020; 11 FM Wang (pmed.1003859.ref044) 2019; 2019 JK Thomas (pmed.1003859.ref050) 2019; 11 |
| References_xml | – volume: 5 start-page: 1125 issue: 6 year: 2016 ident: pmed.1003859.ref014 article-title: Blood lipids and prostate cancer: a Mendelian randomization analysis publication-title: Cancer Med doi: 10.1002/cam4.695 – volume: 59 start-page: 577 issue: 4 year: 2018 ident: pmed.1003859.ref034 article-title: The role of lipoprotein (a) in chronic kidney disease. publication-title: J Lipid Res doi: 10.1194/jlr.R083626 – volume: 113 start-page: 727 issue: 6 year: 2021 ident: pmed.1003859.ref007 article-title: Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research publication-title: JNCI J Natl Cancer Inst doi: 10.1093/jnci/djaa154 – volume: 12 start-page: 31 year: 2017 ident: pmed.1003859.ref052 article-title: Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. publication-title: Clin Res Cardiol Suppl doi: 10.1007/s11789-017-0084-1 – volume: 11 issue: 1 year: 2020 ident: pmed.1003859.ref058 article-title: Selecting likely causal risk factors from high-throughput experiments using multivariable Mendelian randomization. publication-title: Nat Commun. doi: 10.1038/s41467-019-13870-3 – volume: 37 start-page: 658 issue: 7 year: 2013 ident: pmed.1003859.ref024 article-title: Mendelian randomization analysis with multiple genetic variants using summarized data publication-title: Genet Epidemiol doi: 10.1002/gepi.21758 – ident: pmed.1003859.ref002 – volume: 6 year: 2016 ident: pmed.1003859.ref010 article-title: LDL-lowering therapy and the risk of prostate cancer: A meta-analysis of 6 randomized controlled trials and 36 observational studies. publication-title: Sci Rep. – volume: 17 start-page: 874 issue: 6 year: 2015 ident: pmed.1003859.ref006 article-title: Preventing aggressive prostate cancer with proven cardiovascular disease preventive methods publication-title: Asian J Androl doi: 10.4103/1008-682X.156854 – volume: 28 start-page: 208 issue: 1 year: 2019 ident: pmed.1003859.ref015 article-title: Circulating metabolic biomarkers of screen-detected prostate cancer in the ProtecT study publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-18-0079 – volume: 28 start-page: 1331 issue: 8 year: 2019 ident: pmed.1003859.ref032 article-title: Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001–2010. publication-title: Cancer Epidemiol Biomark Prev. doi: 10.1158/1055-9965.EPI-19-0145 – volume: 54 year: 2020 ident: pmed.1003859.ref053 article-title: The opportunity in African genome resource for precision medicine publication-title: EBioMedicine doi: 10.1016/j.ebiom.2020.102721 – volume: 24 start-page: 5471 issue: 21 year: 2018 ident: pmed.1003859.ref051 article-title: IFNL4-ΔG allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-1060 – volume: 99 start-page: 139 issue: 1 year: 2016 ident: pmed.1003859.ref019 article-title: Contrasting the Genetic Architecture of 30 Complex Traits from Summary Association Data publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2016.05.013 – volume: 103 start-page: 76 issue: 1 year: 2014 ident: pmed.1003859.ref031 article-title: Lipoprotein (a): Structure, pathophysiology and clinical implications. publication-title: Arq Bras Cardiol. – volume: 2019 year: 2019 ident: pmed.1003859.ref044 article-title: High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer. publication-title: Dis Markers – volume: 123 start-page: 1693 issue: 7 year: 2008 ident: pmed.1003859.ref056 article-title: Association between plasma cholesterol and prostate cancer in the PSA era publication-title: Int J Cancer doi: 10.1002/ijc.23715 – volume: 123 start-page: 1808 issue: 12 year: 2020 ident: pmed.1003859.ref045 article-title: Examination of potential novel biochemical factors in relation to prostate cancer incidence and mortality in UK Biobank publication-title: Br J Cancer doi: 10.1038/s41416-020-01081-3 – volume: 18 start-page: 2807 issue: 11 year: 2009 ident: pmed.1003859.ref055 article-title: Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-09-0472 – volume: 57 start-page: 1339 issue: 8 year: 2016 ident: pmed.1003859.ref040 article-title: Structure, function, and genetics of lipoprotein (a). publication-title: J Lipid Res doi: 10.1194/jlr.R067314 – volume: 15 issue: 1 year: 2017 ident: pmed.1003859.ref042 article-title: Blood lipids and lipoproteins in relation to incidence and mortality risks for CVD and cancer in the prospective EPIC-Heidelberg cohort publication-title: BMC Med doi: 10.1186/s12916-017-0976-4 – volume: 13 start-page: 173 issue: 2 year: 2010 ident: pmed.1003859.ref033 article-title: The influence of hepatic function on prostate cancer outcomes after radical prostatectomy publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2010.3 – volume: 35 start-page: 4851 issue: 22 year: 2019 ident: pmed.1003859.ref037 article-title: PhenoScanner V2: An expanded tool for searching human genotype-phenotype associations publication-title: Bioinformatics doi: 10.1093/bioinformatics/btz469 – volume: 4 start-page: 330 issue: 4 year: 2017 ident: pmed.1003859.ref013 article-title: Recent Developments in Mendelian Randomization Studies. publication-title: Curr Epidemiol Reports. doi: 10.1007/s40471-017-0128-6 – volume: 7 issue: 6 year: 2012 ident: pmed.1003859.ref046 article-title: The importance of LDL and Cholesterol metabolism for prostate epithelial cell growth publication-title: PLoS ONE doi: 10.1371/journal.pone.0039445 – volume: 32 start-page: 3207 issue: 20 year: 2016 ident: pmed.1003859.ref036 article-title: PhenoScanner: A database of human genotype-phenotype associations publication-title: Bioinformatics doi: 10.1093/bioinformatics/btw373 – start-page: 362 year: 2018 ident: pmed.1003859.ref012 article-title: Reading Mendelian randomisation studies: A guide, glossary, and checklist for clinicians publication-title: BMJ – year: 2021 ident: pmed.1003859.ref018 article-title: Genetics of 35 blood and urine biomarkers in the UK Biobank publication-title: Nat Genet – volume: 3 start-page: 619 issue: 7 year: 2018 ident: pmed.1003859.ref027 article-title: Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: A mendelian randomization analysis. publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2018.1470 – volume: 50 start-page: 693 issue: 5 year: 2018 ident: pmed.1003859.ref029 article-title: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases publication-title: Nat Genet doi: 10.1038/s41588-018-0099-7 – volume: 138 start-page: 2648 issue: 11 year: 2016 ident: pmed.1003859.ref043 article-title: Apolipoproteins, lipids and risk of cancer publication-title: Int J Cancer doi: 10.1002/ijc.30013 – volume: 10 start-page: 63 issue: 2 year: 2019 ident: pmed.1003859.ref001 article-title: Epidemiology of Prostate Cancer. publication-title: World J Oncol doi: 10.14740/wjon1191 – volume: 50 start-page: 928 issue: 7 year: 2018 ident: pmed.1003859.ref020 article-title: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci publication-title: Nat Genet doi: 10.1038/s41588-018-0142-8 – volume: 27 start-page: 995 issue: 9 year: 2018 ident: pmed.1003859.ref011 article-title: Causal inference in cancer epidemiology: What is the role of mendelian randomization? publication-title: Cancer Epidemiol Biomark Prev. doi: 10.1158/1055-9965.EPI-17-1177 – volume: 388 start-page: 2239 issue: 10057 year: 2016 ident: pmed.1003859.ref060 article-title: Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. publication-title: Lancet doi: 10.1016/S0140-6736(16)31009-1 – volume: 8 issue: 9 year: 2018 ident: pmed.1003859.ref049 article-title: Prostate cancer disparities by race and ethnicity: From nucleotide to neighborhood. publication-title: Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a030387 – start-page: 1 year: 2016 ident: pmed.1003859.ref003 article-title: Pathology and epidemiology of cancer publication-title: Pathology and Epidemiology of Cancer – volume: 11 issue: 1 year: 2020 ident: pmed.1003859.ref030 article-title: A robust and efficient method for Mendelian randomization with hundreds of genetic variants. publication-title: Nat Commun. doi: 10.1038/s41467-019-14156-4 – volume: 57 start-page: 1612 issue: 9 year: 2016 ident: pmed.1003859.ref041 article-title: Current therapies for lowering lipoprotein (a). publication-title: J Lipid Res doi: 10.1194/jlr.R053066 – volume: 43 start-page: 922 issue: 3 year: 2014 ident: pmed.1003859.ref038 article-title: Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. publication-title: Int J Epidemiol. doi: 10.1093/ije/dyu005 – volume: 345 year: 2012 ident: pmed.1003859.ref057 article-title: Use of Mendelian randomisation to assess potential benefit of clinical intervention publication-title: BMJ doi: 10.1136/bmj.e7325 – volume: 18 start-page: 2643 issue: 10 year: 2009 ident: pmed.1003859.ref035 article-title: Serum creatinine and prostate cancer risk in a prospective study publication-title: Cancer Epidemiol Biomark Prev doi: 10.1158/1055-9965.EPI-09-0322 – volume: 24 start-page: 1086 issue: 7 year: 2015 ident: pmed.1003859.ref008 article-title: Cholesterol levels in blood and the risk of prostate cancer: A meta-analysis of 14 prospective studies. publication-title: Cancer Epidemiol Biomark Prev. doi: 10.1158/1055-9965.EPI-14-1329 – volume: 326 start-page: 1614 issue: 16 year: 2021 ident: pmed.1003859.ref039 article-title: Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement publication-title: JAMA doi: 10.1001/jama.2021.18236 – volume: 5 start-page: 214 issue: 3 year: 2018 ident: pmed.1003859.ref021 article-title: Understanding the Assumptions Underlying Instrumental Variable Analyses: a Brief Review of Falsification Strategies and Related Tools. publication-title: Curr Epidemiol Reports doi: 10.1007/s40471-018-0152-1 – volume: 48 start-page: 228 issue: 3 year: 2016 ident: pmed.1003859.ref005 article-title: The Risk Factors of Prostate Cancer and Its Prevention: A Literature Review. publication-title: Acta Med Indones – ident: pmed.1003859.ref022 article-title: Guidelines for performing Mendelian randomization investigations. publication-title: Wellcome Open Res. 2020 – volume: 16 start-page: 305 issue: 5 year: 2019 ident: pmed.1003859.ref047 article-title: Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. publication-title: Nat Rev Cardiol doi: 10.1038/s41569-018-0153-2 – volume: 7 issue: 10 year: 2012 ident: pmed.1003859.ref009 article-title: Statin Use and Risk of Prostate Cancer: A Meta-Analysis of Observational Studies. publication-title: PLoS ONE doi: 10.1371/journal.pone.0046691 – volume: 14 issue: 9 year: 2019 ident: pmed.1003859.ref023 article-title: Robust methods in Mendelian randomization via penalization of heterogeneous causal estimates. publication-title: PLoS ONE. – volume: 30 start-page: 87 issue: 1 year: 2016 ident: pmed.1003859.ref059 article-title: Human Genetics and the Causal Role of Lipoprotein(a) for Various Diseases. publication-title: Cardiovasc Drugs Ther. doi: 10.1007/s10557-016-6648-3 – volume: 45 start-page: 1961 issue: 6 year: 2016 ident: pmed.1003859.ref025 article-title: Assessing the suitability of summary data for two-sample mendelian randomization analyses using MR-Egger regression: The role of the I 2 statistic. publication-title: Int J Epidemiol. – volume: 57 start-page: 1111 issue: 7 year: 2016 ident: pmed.1003859.ref048 article-title: Lipoprotein (a): Impact by ethnicity and environmental and medical conditions. publication-title: J Lipid Res doi: 10.1194/jlr.R051904 – volume: 273 start-page: 6 issue: 1 year: 2013 ident: pmed.1003859.ref028 article-title: Lipoprotein(a): Resurrected by genetics. publication-title: J Intern Med doi: 10.1111/j.1365-2796.2012.02592.x – volume: 11 issue: 12 year: 2019 ident: pmed.1003859.ref050 article-title: Racial differences in immunological landscape modifiers contributing to disparity in prostate cancer publication-title: Cancers (Basel). – volume: 36 start-page: 4705 issue: 29 year: 2017 ident: pmed.1003859.ref026 article-title: Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy. publication-title: Stat Med. doi: 10.1002/sim.7492 – volume: 8 issue: 12 year: 2018 ident: pmed.1003859.ref004 article-title: The Epidemiology of Prostate Cancer. publication-title: Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a030361 – ident: pmed.1003859.ref017 – volume: 48 start-page: 498 issue: 6 year: 2011 ident: pmed.1003859.ref016 article-title: Apolipoproteins: Metabolic role and clinical biochemistry applications publication-title: Ann Clin Biochem doi: 10.1258/acb.2011.011111 – volume: 103 start-page: 965 issue: 4 year: 2016 ident: pmed.1003859.ref054 article-title: Best (but oft-forgotten) practices: The design, analysis, and interpretation of Mendelian randomization studies. publication-title: Am J Clin Nutr doi: 10.3945/ajcn.115.118216 |
| SSID | ssj0029090 |
| Score | 2.5283315 |
| Snippet | Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to date. The... Background Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to... Anna Ioannidou and colleagues investigate the relationship between genetically predicted blood lipid concentrations and prostate cancer. BackgroundNumerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to... Background Numerous epidemiological studies have investigated the role of blood lipids in prostate cancer (PCa) risk, though findings remain inconclusive to... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e1003859 |
| SubjectTerms | Age Analysis Apolipoprotein A Apolipoproteins Apolipoproteins - blood Biobanks Biology and Life Sciences Biomarkers Blood lipids Care and treatment Cholesterol Cholesterol, HDL - blood Cholesterol, LDL - blood Datasets Diagnosis Epidemiology Genome-wide association studies Genome-Wide Association Study Genomes High density lipoprotein Humans Lipids Lipids - blood Lipoprotein A Lipoprotein(a) - blood Lipoproteins Low density lipoprotein Male Measurement Medicine and Health Sciences Mendelian Randomization Analysis Pleiotropy Prostate cancer Prostate-specific antigen Prostatic Neoplasms - epidemiology Risk factors Sensitivity analysis Triglycerides United Kingdom |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELXQHhAXRPlqSgGDEJxC48RrJ9wWRFWQWiSgqLfIseM20pJEm92e-enMOE60QSu1B67xc1Y7M_bMODPPhLyJLcQIKbehZCoLwd8WYWrddS-JYkxa5A_BaoszcXLOv17ML7au-sKasJ4euBfc0TzjRmphmbaaK2uUFAWLtImEEia1jr00yqIhmfKpVha50xXkH4OfldI3zSWSHXkdvW_B22CNQJIiT-mWU3Lc_eMOPWuXTbcr_Py3inLLLR0_IPd9PEkX_f_YI3fK-iG5e-q_mD8if8AO6GqoeLuqWuors-iyahvH0lDVdEFVbahrxsLnlekoHtDSFntCIBqlGo1jRbEQ_QOgXRniNaTZ2HhFT_EYHY9LKDg-0_z2FULUUdc-JufHn39-Ogn9rQuhloKvQ2sYRIGiKAoWi7mMsRcV8kIIb2UktYEETGbGRqUtbZyYLOFRmkHSwTKlRcytSp6QWd3U5T6hAvQVmVirTJSwV5hUzAvFlbasULrgNiDJIPZce0pyvBljmbvvbBJSk16KOSor98oKSDjOantKjhvwH1GjIxYJtd0DMLPcm1l-k5kF5CXaQ953p47bQr4QGeOQZXIWkNcOgaQaNVbtXKpN1-Vfvv26BejH2W1A3yegdx5kG5CZVr6dAiSPjF4T5NsJ8rLnM98FPJwAwVz0ZHgf18Ig4y6PwZGCR5AyhZnD-tg9_GocxpdiXV9dNhvAQPSdpqAlHpCn_XIa9ZRA7gDZAcyWk4U2UeR0pK6uHEN6Cl4GdoCD_6H5Z-RejC0vEQtjeUhm69WmfA6B6Lp44facv-e8iA4 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELagSIgXxO8VBhiE4CksThw74QUVxDSQNiRgqG-RY8ddpZKEpuWZP507x8kWVMFe4y9t5POd7853nwl5EVnwEVJuA8lUFsB-WwSpdde9xIoxaZE_BKstTsTRKf80T-Y-4db6ssreJjpDbWqNOfKDCLQWlp-U6dvmZ4C3RuHpqr9C4yq5xsATwasb5Pw84MpCl2NBFjL4cyl961ws2YGX1OsG9hysFIhTZCu9sDU5Bv_BTk-aVd3uckL_rqW8sDkd3iI3vVdJZ90yuE2ulNUdcv3Yn5vfJb9hNdB1X_d2tmyor8-iq2VTO66GZUVnVFWGupYsfL40LcU0LW2wMwR8UqpxiawplqO_AbQrRvwFwTa2X9FjTKZj0oTC9mfqH75OiDoC23vk9PDDt_dHgb97IdBS8E1gDQNfUBRFwSKRyAg7UiE6BCdXhlIbCMNkZmxY2tJGscliHqYZhB4sU1pE3Kr4PplUdVXuESqUNaGJtMpECRbDpCIpFFfaskLpgtspiftpz7UnJsf7MVa5O22TEKB0s5ijsHIvrCkJhreajpjjP_h3KNEBi7Ta7kG9XuReS_Mk40ZqYZm2msNnKykKFmoTCiVMapMpeYrrIe96VAfjkM9ExjjEmpxNyXOHQGqNCmt3FmrbtvnHz98vAfp6chnQlxHolQfZGuZMK99UATOPvF4j5MsRctGxmu8C7o-AsFz0aHgPdaGf4zY_V0x4s9eP3cPPhmH8Uazuq8p6CxjwwdMUpMSn5EGnToOcYoggIEaAt-VI0UaCHI9UyzPHk57CXgMW4OG_P-sRuRFhS0vIgkjuk8lmvS0fg6O5KZ44a_IHCCh9_g priority: 102 providerName: ProQuest |
| Title | The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35085228 https://www.proquest.com/docview/2762183778 https://www.proquest.com/docview/2623883854 https://pubmed.ncbi.nlm.nih.gov/PMC8794090 https://doaj.org/article/594d7c6f1cfc4afda76b10cd06a6d8f5 http://dx.doi.org/10.1371/journal.pmed.1003859 |
| Volume | 19 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe2Tpr2gvheYRSDEDxlihPXTpAQ6tCmAVqBwVDfIseOu0olKU2L4I0_nTvnQwQVMfGSh_jnKLrz-e7s-yDkSWDBRoi49SRTsQf6NvUi69q9hIoxabF-CEZbjMXpBX8zGU62SNOztSZgudG1w35SF8v54fevP16CwL9wXRskayYdLkB_4K1_GA3jbbLjbowwmI-39wpB7LtTF6xLBr8jZZ1M97ev7JHdECwYsFGijt5y5f3bTby3mBflJgv1z0DL3zTXyXVyrTY56ahaIzfIVpbfJLtn9aX6LfITlgpdNkFxl7MFrYO36Hy2KFwhh1lOR1Tlhrp8LXw_MyXFM1y6wLQRMFipxvWzpBir_hzQLlLxG3jimJtFz_CkHU9UKOhGU3ypg4ioq257m1ycHH96derVjRk8LQVfedYwMBRFmqYsEEMZYLoquI5gAUtfagM-moyN9TOb2SA0ccj9KAa_hMVKi4BbFd4hvbzIs31ChbLGN4FWschgOzGRGKaKK21ZqnTKbZ-EDdkTXVctx-YZ88RdxUnwXioqJsi3pOZbn3jtrEVVteMf-CPkaIvFmtvuRbGcJrUIJ8OYG6mFZdpqDr-tpEiZr40vlDCRHfbJQ1wPSZXA2u4cyUjEjIMjylmfPHYIrLuRY2DPVK3LMnn97vMVQB_HVwGdd0DPapAtgGZa1RkXQHks-tVBPu0gp1XJ803Agw4QlovuDO-jLDQ0LpMAdC0oDSkjmNnIx-bhR-0wfhRD__KsWAMGDPQoAi7xPrlbiVPLp0Y4-0R2BK3DyO5IPrt0RdQjUESwGdz775n3yV6AqTA-8wJ5QHqr5Tp7AAbqKh2QbTmRA7JzdDx-fz5wxzzwfPshGrjd6Bcq1JV5 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiHcXCjWIxyk0Trx2glShFlq1tF1QH6i34Nhxu1JJwm4L4sYv47cx43VCgyropdd4HCWe8TzsmW8IeRZZ8BESbgPJVBqAvc2DxLp2L7FiTFrED8Fsi6FY3-fvDwYHM-RXUwuDaZWNTnSK2lQaz8gXI9i1IH5SJm_qrwF2jcLb1aaFhvKtFcySgxjzhR2bxY_vEMJNljbeAb-fR9Ha6t7b9cB3GQi0FPwksIaB1yPyPGeRGMgIay8hDgJ3ToZSGwg4ZGpsWNjCRrFJYx4mKTjZLFVaRNyqGN57hcxyPEDpkdmV1eHHnTbkS0N3yoM4aPD7UvrivViyRS8rr2qwepirECeIl3rGOLoeAq2l6NXH1eQ8N_jvbM4z5nHtJrnh_Vq6PBXEW2SmKG-Tq9v-5v4O-QnySMdN5t3RqKY-Q4wej-rKoUWMSrpMVWmoKwrD5yMzoXhQTGusTQGvmGoU0jHFhPjXQO3SIb9BuI8FYHQbj_Px2IaCATbVF5-pRB2E7l2yfyl8uUd6ZVUWc4QKZU1oIq1SUYDOMokY5IorbVmudM5tn8TNsmfaQ6Njh47jzN33SQiRpquYIbMyz6w-CdpZ9RQa5D_0K8jRlhaBvd2DanyYeT2RDVJupBaWaas5fLaSImehNqFQwiR20CcLKA_ZtEq2VU_ZskgZh2iXsz556igQ3KPE7KFDdTqZZBsfPl2AaHd4EaKdDtFLT2QrWDOtfFkHrDwii3UoX3QoD6e46ucRzncIQVx0Z3gO90KzxpPsj2qAmc3-OH_4STuML8X8wrKoToEGooAkAS7xPrk_3U4tn2KIYSBKgdmys9E6jOyOlKMjh9SegLUDDfDg35-1QK6t721vZVsbw82H5HqEBTYhCyI5T3on49PiEbi9J_ljr1so-XzZ6uw3yNe_ag |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKIlVcEO8uFGoQj1NonHjtBAmhhVK1lBYEFPUWHDtuV1qSsA8QN34Xv44Zx9k2qIJeeo0_R4nnbc-MCXkYWfAREm4DyVQagL3Ng8S6615ixZi02D8Esy32xNY-f3MwOFgiv9taGEyrbHWiU9Sm0rhHvh6B1AL7SZmsW58W8X5j80X9LcAbpPCktb1Oo2GRneLnDwjfps-3N4DWj6Jo8_WnV1uBv2Eg0FLwWWANA49H5HnOIjGQEdZdQgwErpwMpTYQbMjU2LCwhY1ik8Y8TFJwsFmqtIi4VTG89wK5KGMw6yBL8uA42EtDt7-DHdDgx6X0ZXuxZOueS57WYO8wSyFOsFPqCbPobg9Y2IhePa6mpznAf-dxnjCMm1fIZe_R0mHDglfJUlFeI8u7_sz-OvkFnEgnbc7d0aimPjeMjkd15fpEjEo6pKo01JWD4fORmVLcIqY1VqWAP0w1sueEYir8M0C7RMjvEOhj6RfdxY183LChYHpN9dXnKFHXPPcG2T8XqtwkvbIqixVChbImNJFWqShAW5lEDHLFlbYsVzrntk_idtkz7Zui490c48yd9EkIjppVzJBYmSdWnwSLWXXTFOQ_-JdI0QUWW3q7B9XkMPMaIhuk3EgtLNNWc_hsJUXOQm1CoYRJ7KBP1pAfsqY-dqGYsqFIGYc4l7M-eeAQ2NajRAE5VPPpNNt-9_kMoI97ZwF96ICeeJCtYM208gUdsPLYU6yDfNxBHjYd1U8DrnaAwC66M7yCstCu8TQ7Vgows5WP04fvL4bxpZhZWBbVHDDg_ycJUIn3ya1GnBZ0iiF6gfgEZsuOoHUI2R0pR0euR3sCdg40wO1_f9YaWQYllr3d3tu5Qy5FWFkTsiCSq6Q3m8yLu-DvzvJ7TrFQ8uW8NdkfupG9Dg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+relationship+between+lipoprotein+A+and+other+lipids+with+prostate+cancer+risk%3A+A+multivariable+Mendelian+randomisation+study&rft.jtitle=PLoS+medicine&rft.au=Ioannidou%2C+Anna&rft.au=Watts%2C+Eleanor+L.&rft.au=Perez-Cornago%2C+Aurora&rft.au=Platz%2C+Elizabeth+A.&rft.date=2022-01-27&rft.pub=Public+Library+of+Science&rft.issn=1549-1277&rft.eissn=1549-1676&rft.volume=19&rft.issue=1&rft_id=info:doi/10.1371%2Fjournal.pmed.1003859&rft_id=info%3Apmid%2F35085228&rft.externalDocID=PMC8794090 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon |